Instil Bio, Inc.
Moat Score — Instil Bio, Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 1 / 5 | Instil holds patents and know-how tied to discontinued programs (ITIL-168/306 TIL cell therapy, the licensed AXN-2510 bispecific), but with no active candidate left in development, these IP assets currently generate no value and provide no real barrier to entry for anyone. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Instil has no commercial product and no manufacturing scale advantage; its Tarzana facility is leased out to AstraZeneca rather than used for its own low-cost production, so there is no cost-advantage moat whatsoever. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With zero product revenue and no candidate in active trials, Instil has no pricing power of any kind today — there is nothing to price. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Biotech licensing and drug development carry no network effects, and Instil's in-license/acquire model does not create any user- or data-driven flywheel. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | The one real switching-cost asset is AstraZeneca's lease of the Tarzana manufacturing facility, which AstraZeneca would face real cost and time to relocate out of, but this is a single counterparty relationship, not a broad switching-cost moat across a customer base. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The Tarzana facility is a large, specialized cell/gene therapy manufacturing asset that would be costly to replicate, giving Instil a modest scale-related asset, but the company itself operates at a tiny scale (17 employees) with no efficient-scale advantage in its actual business of drug licensing. |